National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

R-flurbiprofen
An orally active synthetic enantiomer of flurbiprofen. R-flurbiprofen activates c-Jun N terminal kinase, increases AP-1 binding to DNA, and downregulates cyclin D1 expression, resulting in arrest of tumor cells in the G1 phase of the cell cycle and apoptosis. This agent also affects the expression of nuclear factor kappa B, a rapid response transcription factor that stimulates the immune response to tumor cells. R-flurbiprofen does not inhibit the enzyme cyclo-oxygenase. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

US brand name:Flurizan
Code names:E-7869
MPC-7869
Chemical structure name:(R)-2-Fluoro-alpha-methyl[1,1'-biphenyl]-4-acetic Acid



Previous:Quixin, Qvar, R(+)XK469, R-(-)-gossypol acetic acid, R-CHOP regimen
Next:racemic XK469, RadiaPlex Rx Gel, Raf kinase inhibitor XL281, raloxifene, raltitrexed

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov